secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-08-03T21:15:26+00:00
Accession:  0001628280-26-051964
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026
--------------------------------------------------------------------------------

- Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.
- Merger still requires regulatory and shareholder approvals; expected close in Q4 2026.
- Repligen describes itself as a bioprocessing tools company with ~2,000 employees globally.
- BioLife's CryoStor platform supports majority of US cell-based therapy trials.
- Until close, BioLife and Repligen will operate as separate independent companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/0001628280-26-051964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/blfs-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer